Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTIrreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksTjeerd Barf* and Allard KapteinView Author Information Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands*Phone: +31 618 193139. E-mail, [email protected]Cite this: J. Med. Chem. 2012, 55, 14, 6243–6262Publication Date (Web):May 23, 2012Publication History Received7 March 2012Published online8 June 2012Published inissue 26 July 2012https://pubs.acs.org/doi/10.1021/jm3003203https://doi.org/10.1021/jm3003203review-articleACS PublicationsCopyright © 2012 American Chemical SocietyRequest reuse permissionsArticle Views13870Altmetric-Citations266LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Inhibition,Inhibitors,Kinase inhibitors,Monomers,Peptides and proteins Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [45]
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Research works printed but not linked: 5
- Powis G., 1994, Cancer Res., 54, 2419
- Wood E. R., 2008, Proc. Natl. Acad. Sci. U.S.A., 105, 2772
- Brigdes A. J., 2000, Chem. Rev., 101, 2541
- Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18, 2011.
- Petter, R.Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23, 2011.
Cited by
Items 101–200 of 386
Bensinger, D., Stubba, D., Cremer, A., Kohl, V., Waßmer, T., Stuckert, J., Engemann, V. I., Stegmaier, K., Schmitz, K., & Schmidt, B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01714 · Cited by 50
Fumarola, C., Bozza, N., Castelli, R., Ferlenghi, F., Marseglia, G., Lodola, A., Bonelli, M. A., Monica, S. L., Cretella, D., Alfieri, R. R., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00179 · Cited by 48
Li, B., Li, Y., Tomkiewicz-Raulet, C., Dao, P., Lietha, D., Yen‐Pon, E., Du, Z., Coumoul, X., Garbay, C., Ethève‐Quelquejeu, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01059 · Cited by 51
Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
Pei, H., He, L., Shao, M., Yang, Z., Ran, Y., Li, D., Zhou, Y., Tang, M., Wang, T., Gong, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23569-y · Cited by 50
Kinases inhibitors in lung cancer: From benchside to bedside
Singh, P. K., Singh, H., & Silakari, O. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.07.002 · Cited by 48
New drug design with covalent modifiers
Adeniyi, A. A., Ramesh, M., & Soliman, M. E. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1115478 · Cited by 48
Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine
Kwarcinski, F. E., Fox, C. C., Steffey, M. E., & Soellner, M. B. (2012) · ACS Chemical Biology · doi:10.1021/cb300337u · Cited by 46
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
Joseph, R. E., Amatya, N., Fulton, D. B., Engen, J. R., Wales, T. E., & Andreotti, A. H. (2020) · eLife · doi:10.7554/elife.60470 · Cited by 47
Ding, Y., Li, D., Ding, C., Wang, P., Liu, Z., Wold, E. A., Ye, N., Chen, H., White, M. A., Shen, Q., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01514 · Cited by 45
Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign
Baillie, T. A. (2016) · Angewandte Chemie · doi:10.1002/ange.201601091 · Cited by 44
Nassar, H., Sippl, W., Abu‐Dahab, R., & Taha, M. O. (2023) · RSC Advances · doi:10.1039/d3ra01145c · Cited by 42
Bianco, G., Goodsell, D. S., & Forli, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.005 · Cited by 44
Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines
Sato, M., Fuchida, H., Shindo, N., Kuwata, K., Tokunaga, K., Xiao-Lin, G., Inamori, R., Hosokawa, K., Watari, K., Shibata, T., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00574 · Cited by 41
Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors
Smith, D. E., Marquez, I., Lokensgard, M. E., Rheingold, A. L., Hecht, D., & Gustafson, J. L. (2015) · Angewandte Chemie · doi:10.1002/ange.201506085 · Cited by 40
Recent Developments and Advances of FGFR as a Potential Target in Cancer
Xue, W.-J., Li, M., Chen, L., Sun, L., & Li, Y. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0103 · Cited by 42
Benjamin, M. A. Z., Mokhtar, R. A. M., Iqbal, M., Abdullah, A., Azizah, R., Sulistyorini, L., Mahfudh, N., & Zakaria, Z. A. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118239 · Cited by 50
Chirumamilla, C. S., Perez-Novo, C. A., Ostade, X. V., & Berghe, W. V. (2017) · Proceedings of The Nutrition Society · doi:10.1017/s0029665116002937 · Cited by 38
Ficarro, S. B., Browne, C. M., Card, J. D., Alexander, W. M., Zhang, T., Park, E., McNally, R., Dhe‐Paganon, S., Seo, H., Lamberto, I., et al. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03394 · Cited by 36
Yen‐Pon, E., Li, B., Acebrón-García-de-Eulate, M., Tomkiewicz, C., Dawson, J. C., Lietha, D., Frame, M. C., Coumoul, X., Garbay, C., Ethève‐Quelquejeu, M., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00250 · Cited by 38
Wu, K.-D., Chen, G. S., Liu, J.-R., Hsieh, C.-E., & Chern, J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00270 · Cited by 37
Sun, J., Zhong, H., Wang, K., Li, N., & Chen, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.023 · Cited by 40
Covalent chemical probes for protein kinases
Serafim, R. A. M., Haarer, L., Pedreira, J. G. B., & Gehringer, M. (2023) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100040 · Cited by 35
Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents
Liu, L., Kong, C., Fumagalli, M., Savková, K., Xu, Y., Huszár, S., Sammartino, J. C., Fan, D., Chiarelli, L. R., Mikušová, K., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112773 · Cited by 37
Bavi, R., Kumar, R., Choi, L., & Lee, K. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147190 · Cited by 38
Covalent Inhibitors: Back on track?
Gehringer, M. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0118 · Cited by 41
Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides
Charoenpattarapreeda, J., Tan, Y. S., Iegre, J., Walsh, S. J., Fowler, E., Eapen, R. S., Wu, Y., Sore, H. F., Verma, C. S., Itzhaki, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04022f · Cited by 35
Targeting Protein Kinases with Selective and Semipromiscuous Covalent Inhibitors
Miller, R. M., & Taunton, J. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-397918-6.00004-5 · Cited by 42
Kawahata, W., Asami, T., Kiyoi, T., Irie, T., Taniguchi, H., Asamitsu, Y., Inoue, T., Miyake, T., & Sawa, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01147 · Cited by 36
Zhang, C., Hu, Y., Sun, P., Hua, L., Liang, S., Ou, Y., Wu, D., Wu, X., Chen, H. H., Hao, Y., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113417 · Cited by 34
Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines
Temburnikar, K. W., Zimmermann, S. C., Kim, N. T., Ross, C. R., Gelbmann, C. B., Salomon, C. E., Wilson, G. M., Balzarini, J. M., & Seley‐Radtke, K. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.033 · Cited by 37
Punthasee, P., Laciak, A. R., Cummings, A. H., Ruddraraju, K. V., Lewis, S. M., Hillebrand, R., Singh, H., Tanner, J. J., & Gates, K. S. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00151 · Cited by 34
Chen, X., Du, Y., Sun, H., Wang, F., Kong, L., & Sun, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.079 · Cited by 35
Buffa, P., Romano, C., Pandini, A., Massimino, M., Tirrò, E., Raimondo, F. D., Manzella, L., Fraternali, F., & Vigneri, P. G. (2013) · The FASEB Journal · doi:10.1096/fj.13-236992 · Cited by 34
Xu, S., Xu, T., Zhang, L., Zhang, Z., Luo, J., Liu, Y., Lu, X., Tu, Z., Ren, X., & Ding, K. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012388 · Cited by 33
Sun, X., Xu, S., Yang, Z., Zheng, P., & Zhu, W. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1860210 · Cited by 34
Das, D., Wang, J., & Hong, J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100166 · Cited by 37
Chemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 33
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor
Serafim, R. A. M., Santiago, A. D. S., Schwalm, M. P., Hu, Z., dos Reis, C. V., Takarada, J. E., Mezzomo, P., Massirer, K. B., Kudolo, M., Gerstenecker, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01165 · Cited by 36
de Araujo, A. D., Lim, J., Good, A. C., Skerlj, R. T., & Fairlie, D. P. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00395 · Cited by 36
Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging
Bernard‐Gauthier, V., Bailey, J. J., Berke, S., & Schirrmacher, R. (2015) · Molecules · doi:10.3390/molecules201219816 · Cited by 34
Characterization of Covalent-Reversible EGFR Inhibitors
Smith, S. P., Keul, M., Engel, J., Basu, D., Eppmann, S., & Rauh, D. (2017) · ACS Omega · doi:10.1021/acsomega.7b00157 · Cited by 35
Chen, D., Guo, D., Yan, Z., & Zhao, Y. (2017) · MedChemComm · doi:10.1039/c7md00571g · Cited by 32
Lin, X., Yosaatmadja, Y., Kalyukina, M., Middleditch, M., Zhang, Z., Lu, X., Ding, K., Patterson, A. V., Smaill, J. B., & Squire, C. J. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00196 · Cited by 31
Kaspersen, S. J., Han, J., Nørsett, K. G., Rydså, L., Kjøbli, E., Bugge, S., Bjørkøy, G., Sundby, E., & Hoff, B. H. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.04.011 · Cited by 35
Liu, N., Hoogendoorn, S., van de Kar, B., Kaptein, A., Barf, T. A., Driessen, C., Filippov, D. V., van der Marel, G. A., van der Stelt, M., & Overkleeft, H. S. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00474h · Cited by 30
Self-citationcBinderDB: a covalent binding agent database
Du, J., Yan, X., Liu, Z., Cui, L., Ding, P., Tan, X., Li, X., Zhou, H., Gu, Q., & Xu, J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw801 · Cited by 30
Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF
Giroux, S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.037 · Cited by 34
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S N Ar Electrophiles
Schwarz, M., Kurkunov, M., Wittlinger, F., Rudalska, R., Wang, G., Schwalm, M. P., Rasch, A., Wagner, B., Laufer, S., Knapp, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02483 · Cited by 32
Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches
Zhang, Y., Zhang, D., Tian, H.-Z., Jiao, Y., Shi, Z., Ran, T., Liu, H., Lü, S., Xu, A., Qiao, X., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00302 · Cited by 35
Carramiñana, V., de Retana, A. M. O., del Burgo, A. V., Santos, J. M. D. L., & Palácios, F. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.002 · Cited by 29
Wolle, P., Hardick, J., Cronin, S. J. F., Engel, J., Baumann, M., Lategahn, J., Penninger, J. M., & Rauh, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00102 · Cited by 31
Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment
Ceramella, J., Iacopetta, D., Barbarossa, A., Caruso, A., Grande, F., Bonomo, M. G., Mariconda, A., Longo, P., Saturnino, C., & Sinicropi, M. S. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200117144701 · Cited by 30
Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK
Förster, M., Liang, X. J., Schröder, M., Gerstenecker, S., Chaikuad, A., Knapp, S., Laufer, S., & Gehringer, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239269 · Cited by 30
Li, X., Guise, C. P., Taghipouran, R., Yosaatmadja, Y., Ashoorzadeh, A., Paik, W.-K., Squire, C. J., Jiang, S., Luo, J., Xu, Y., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.049 · Cited by 28
Venetsanakos, E., Brameld, K. A., Phan, V. T., Verner, E. J., Owens, T. D., Xing, Y., Tam, D., LaStant, J., Leung, K., Karr, D. E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0309 · Cited by 27
Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors
Xiao, Z., Chu, C., Zhou, L., Zhou, Z., Zhang, Q., Yang, F., Yang, Z., Zheng, P., Xu, S., & Zhu, W. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115669 · Cited by 27
Liang, X., Lv, F., Wang, B., Yu, K., Wu, H., Qi, Z., Jiang, Z., Chen, C., Wang, A., Miao, W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01413 · Cited by 27
Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
Niggenaber, J., Hardick, J., Lategahn, J., & Rauh, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00964 · Cited by 30
Lebraud, H., Coxon, C. R., Archard, V. S., Bawn, C., Carbain, B., Matheson, C. J., Turner, D. M., Cano, C., Griffin, R. J., Hardcastle, I. R., et al. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41806e · Cited by 26
Huang, Y., Wei, L., Han, X., Chen, H., Ren, Y., Xu, Y., Song, R., Rao, L., Chen, S., Peng, C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111749 · Cited by 24
Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors
He, L., Shao, M., Wang, T., Lan, T., Zhang, C., & Chen, L. (2018) · Molecular Diversity · doi:10.1007/s11030-017-9803-2 · Cited by 25
Zhang, Z., Wang, Y., Chen, X., Song, X., Tu, Z., Chen, Y., Zhang, Z., & Ding, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116457 · Cited by 24
Han, W., & Du, Y. (2017) · Chemistry & Biodiversity · doi:10.1002/cbdv.201600372 · Cited by 26
Podoll, T., Pearson, P. G., Kaptein, A., Evarts, J., de Bruin, G., Hoek, M. E.-V., de Jong, A., van Lith, B., Sun, H., Byard, S. J., et al. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001116 · Cited by 28
Self-citationHan, C., Wan, L., Ji, H., Ding, K., Huang, Z., Lai, Y., Peng, S., & Zhang, Y. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.032 · Cited by 25
Sameshima, T., Yamamoto, T., Sano, O., Sogabe, S., Igaki, S., Sakamoto, K., Ida, K., Gotou, M., Imaeda, Y., Sakamoto, J., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b00732 · Cited by 27
Covalent Kinase Inhibitors: An Overview
Gehringer, M. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_103 · Cited by 27
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations
Lodola, A., Callegari, D., Scalvini, L., Rivara, S., & Mor, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_19 · Cited by 25
Technologies for Direct Detection of Covalent Protein–Drug Adducts
Mons, E., Kim, R. Q., & Mulder, M. P. C. (2023) · Pharmaceuticals · doi:10.3390/ph16040547 · Cited by 26
Epidermal growth factor receptor inhibitors: a patent review (2010 – present)
Li, S., & Li, H. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.871527 · Cited by 22
Wurz, R. P., Pettus, L. H., Ashton, K., Brown, J., Chen, J. J., Herberich, B., Hong, F., Harrington, E. H., Nguyen, T. T., Jean, D. J. S., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00193 · Cited by 29
Yin, Y., Chen, C., Yu, R.-N., Shu, L., Wang, Z., Zhang, T., & Zhang, D. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103720 · Cited by 21
An Updated Overview on the Synthesis and Anticancer Evaluation of Quinazoline Derivatives
Kaur, J., Kaur, S., Ȧnand, A., Islam, N., Singh, S., & Singh, A. (2023) · ChemistrySelect · doi:10.1002/slct.202302778 · Cited by 25
Zhang, S., Xu, Y., Jin, E., Zhu, L., Xia, B., Chen, X., Li, F., & Ma, S. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.116 · Cited by 23
Opportunities and challenges for the development of covalent chemical immunomodulators
Backus, K. M., Cao, J. X., & Maddox, S. M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.050 · Cited by 21
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53
Klett, T., Schwer, M., Ernst, L. N., Engelhardt, M. U., Jaag, S., Masberg, B., Knappe, C., Lämmerhofer, M., Gehringer, M., & Boeckler, F. M. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s466829 · Cited by 23
Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core
Xu, J., Ong, E. H., Hill, J., Chen, A., & Chai, C. L. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.10.006 · Cited by 20
BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals
Pu, S., Schor, S., Karim, M., Saul, S., Robinson, M., Kumar, S., Prugar, L. I., Dorosky, D. E., Brannan, J. M., Dye, J. M., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104966 · Cited by 21
Jung, Y., Noda, N., Takaya, J., Abo, M., Toh, K., Tajiri, K., Cui, C., Zhou, L., Sato, S., & Uesugi, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00824 · Cited by 20
Pulz, R., Angst, D., & Cenni, B. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177747 · Cited by 22
Kovalent‐allosterische Kinase‐Inhibitoren
Weisner, J., Gontla, R., Westhuizen, L. V. D., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201502142 · Cited by 19
Tian, L., Qiang, T., Yang, X., Yue, G., Zhai, X., Kang, K., Du, C., Lu, Q., Gao, H., Zhang, D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115979 · Cited by 20
Recent Advances in Irreversible Kinase Inhibitors
Gilbert, A. M. (2014) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.14.24 · Cited by 18
Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation
Nguyen, T., Coover, R. A., Verghese, J., Moran, R. G., & Ellis, K. C. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500088x · Cited by 19
Carboxylic Acid Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Lou, Y. C., & Zhu, J. (2016) · Wiley-VCH eBooks · doi:10.1002/9783527693931.ch16 · Cited by 22
Daniele, S., Barresi, E., Zappelli, E., Marinelli, L., Novellino, E., Settimo, F. D., Taliani, S., Trincavelli, M. L., & Martini, C. (2016) · Oncotarget · doi:10.18632/oncotarget.6872 · Cited by 19
Castelli, R., Bozza, N., Cavazzoni, A., Bonelli, M. A., Vacondio, F., Ferlenghi, F., Callegari, D., Silva, C., Rivara, S., Lodola, A., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.029 · Cited by 17
The Current Toolbox for Covalent Inhibitors: From Hit Identification to Drug Discovery
You, M., Liu, H., & Li, C. (2025) · JACS Au · doi:10.1021/jacsau.5c01134 · Cited by 24
Faris, A., Ibrahim, I. M., Alnajjar, R. A., Hadni, H., Bhat, M. A., Yaseen, M., Chakraborty, S., Alsakhen, N. A., Shamkh, I. M., Mabood, F., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2283168 · Cited by 21
Bugge, S., Moen, I. U., Sylte, K.-O. K., Sundby, E., & Hoff, B. H. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.004 · Cited by 17
Ogiyama, T., Yamaguchi, M., Kurikawa, N., Honzumi, S., Yamamoto, Y., Sugiyama, D., & Inoue, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.022 · Cited by 16
He, L., Li, D., Zhang, C., Bai, P., & Chen, L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.009 · Cited by 18
Seetaha, S., Ratanabanyong, S., & Choowongkomon, K. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10116-6 · Cited by 16
Wang, X., Xue, G., & Pan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111918 · Cited by 16
van der Wel, T., Hilhorst, R., den Dulk, H., van den Hooven, T., Prins, N., Wijnakker, J. J. A. P. M., Florea, B. I., Lenselink, E. B., van Westen, G. J. P., Ruijtenbeek, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17027-5 · Cited by 17
Self-citationSabat, M., Dougan, D. R., Knight, B., Lawson, J. D., Scorah, N., Smith, C. R., Taylor, E. R., Vu, P., Wyrick, C., Wang, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01026 · Cited by 17
Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines
Temburnikar, K. W., Ross, C. R., Wilson, G. M., Balzarini, J. M., Cawrse, B. M., & Seley‐Radtke, K. L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.025 · Cited by 16
Fei, W.-L., Wang, Y., Feng, Q.-L., Li, C.-T., Jiang, R.-X., Zhang, S.-D., Pan, Y., Ni, P.-F., Huang, F.-R., Huangfu, Y.-B., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117183 · Cited by 17
Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors
Kawahata, W., Asami, T., Irie, T., & Sawa, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.037 · Cited by 15
Erbay, T. G., Dempe, D. P., Godugu, B., Liu, P., & Brummond, K. M. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c01335 · Cited by 15
Metadata
- Authors
- Barf, T., & Kaptein, A.
- Affiliations
- Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands
- Corresponding author
- Barf, Tjeerd
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-06-08
- Volume
- 55
- Issue
- 14
- Pages
- 6243-6262
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2057079741
- Cited by
- 331
- References
- 108
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 21 · 2023: 17 · 2022: 9 · 2021: 30 · 2020: 38 · 2019: 26 · 2018: 22 · 2017: 38 · 2016: 32 · 2015: 22 · 2014: 25 · 2013: 14 · 2012: 7
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- kinase inhibitors, covalent inhibitors, drug development, benefits and risks, kinase-targeted therapy
- MeSH terms
- Animals, Cell Line, Humans, Protein Kinases, Risk, Structure-Activity Relationship, Time Factors, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.